20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
15:31 MIN
- CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
15:18 MIN
- CIDP
- GBS
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
Wear-Off in IVIG and What it Means in Clinical Practice
16:21 MIN
- CIDP
Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.
SELECT A CHAPTER TO VIEW
Introduction
Introduction to wear-off effects
Monitoring wear-off effects
Combating wear-off effects
Conclusion
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
12:50 MIN
- CIDP
- MMN
Review options for individualizing treatment and tools used to assess IgG performance
NOW PLAYING
15:31
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
NOW PLAYING
15:18
Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.
NOW PLAYING
16:21
Wear-Off in IVIG and What it Means in Clinical Practice
Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.
NOW PLAYING
12:50
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
Review options for individualizing treatment and tools used to assess IgG performance
Our Experts on CIDP
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
- CIDP
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
Thomas Harbo, MD, PhD
Aarhus University Hospital in Aarhus, Denmark
- CIDP
- GBS
Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
- CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
- CIDP
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.
Slides & Posters about CIDP
Clinical Studies for the Treatment of CIDP with Immunoglobulin
PDF | 396 KB
CIDP Assessment Tools: Grip Strength
PDF |
Fatigue in CIDP
PDF | 1.23 MB
Wear-Off in IVIG and What it Means in Clinical Practice
PDF |
Back to Top